Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Bridgewater

Showing results (51-60 of 124) with videos related to

Pageof 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2016
BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal CancerAl B Benson, Igor Kiss, John Bridgewater, et al.
Journal of Medical Imaging and Radiation Oncology|May 16, 2020
Predictors of patient preference for either whole body magnetic resonance imaging (WB-MRI) or CT/ PET-CT for staging colorectal or lung cancerAnne Miles, Ruth Ec Evans, Steve Halligan, et al.
BMC Cancer|August 1, 2015
Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trialAlexander Stein, Dirk Arnold, John Bridgewater, et al.
The Oncologist|November 19, 2020
A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)Mairéad G McNamara, John Bridgewater, Daniel H Palmer, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2015
Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancerMie Grunnet, Ib J Christensen, Ulrik Lassen, et al.
Cancer Chemotherapy and Pharmacology|June 5, 2003
Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancerBruno Reigner, Toru Watanabe, Johannes Schüller, et al.
Cancer Discovery|September 23, 2021
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring <i>FGF</i>/<i>FGFR</i> Aberrations: A Phase I Dose-Expansion StudyFunda Meric-Bernstam, Rastislav Bahleda, Cinta Hierro, et al.
Cancer Treatment and Research Communications|August 30, 2022
Prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100,000 genomes projectJohn Bridgewater, Xiaolong Jiao, Mounika Parimi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 18, 2010
R0 but not R1/R2 resection is associated with better survival than palliative photodynamic therapy in biliary tract cancerWolf-Rudiger Matull, Dipok K Dhar, Lakshmana Ayaru, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2004
Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancerLia van Zuylen, John Bridgewater, Alex Sparreboom, et al.
Pageof 13

Showing results (51-60 of 124) with videos related to

Sort By:
Pageof 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2016
BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal CancerAl B Benson, Igor Kiss, John Bridgewater, et al.
Journal of Medical Imaging and Radiation Oncology|May 16, 2020
Predictors of patient preference for either whole body magnetic resonance imaging (WB-MRI) or CT/ PET-CT for staging colorectal or lung cancerAnne Miles, Ruth Ec Evans, Steve Halligan, et al.
BMC Cancer|August 1, 2015
Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trialAlexander Stein, Dirk Arnold, John Bridgewater, et al.
The Oncologist|November 19, 2020
A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)Mairéad G McNamara, John Bridgewater, Daniel H Palmer, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2015
Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancerMie Grunnet, Ib J Christensen, Ulrik Lassen, et al.
Cancer Chemotherapy and Pharmacology|June 5, 2003
Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancerBruno Reigner, Toru Watanabe, Johannes Schüller, et al.
Cancer Discovery|September 23, 2021
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring <i>FGF</i>/<i>FGFR</i> Aberrations: A Phase I Dose-Expansion StudyFunda Meric-Bernstam, Rastislav Bahleda, Cinta Hierro, et al.
Cancer Treatment and Research Communications|August 30, 2022
Prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100,000 genomes projectJohn Bridgewater, Xiaolong Jiao, Mounika Parimi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 18, 2010
R0 but not R1/R2 resection is associated with better survival than palliative photodynamic therapy in biliary tract cancerWolf-Rudiger Matull, Dipok K Dhar, Lakshmana Ayaru, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2004
Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancerLia van Zuylen, John Bridgewater, Alex Sparreboom, et al.
Pageof 13